Mylotarg™ (gemtuzumab ozogamicin)

MYLOTARG is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL)1

PP-MYL-GBR-0085. December 2019


1. MYLOTARG™ Summary of Marketing Product Characteristics.

Prescribing information

MYLOTARG™ (gemtuzumab ozogamicin) 5 mg powder for concentrate for solution for infusion
Legal category: Prescription only medicine.  Cost: £6,300 per vial.

Click here to access the MYLOTARG Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.

 ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Cytarabine 20 mg/mL and 100 mg/mL solution for infusion or injection

Legal category: Prescription only medicine. Basic NHS price: Cytarabine 100 mg/mL, supplied as single vials containing 100 mg/mL cytarabine in 10 mL (1 g), £39.00 or 20 mL (2 g), £77.50. Cytarabine 20 mg/mL supplied as vials containing 20 mg/mL cytarabine in 5 mL (100 mg) in packs of 5, £20.48 or 25 mL (500 mg) as single vials, £19.50. 
Click to access the cytarabine
20 mg/mL and 100 mg/mL Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.